Fong L - Search Results

1

Unmasking the immune recognition of prostate cancer with CTLA4 blockade.

Kwek SS, Cha E, Fong L. Kwek SS, et al. Among authors: fong l. Nat Rev Cancer. 2012 Mar 1;12(4):289-97. doi: 10.1038/nrc3223. Nat Rev Cancer. 2012. PMID: 22378189 Free PMC article. Review.

2

Immunotherapy for prostate cancer.

Fong L, Small EJ. Fong L, et al. Semin Oncol. 2003 Oct;30(5):649-58. doi: 10.1016/s0093-7754(03)00350-6. Semin Oncol. 2003. PMID: 14571412 Review.

3

Immunotherapy for prostate cancer.

Fong L, Small EJ. Fong L, et al. Curr Urol Rep. 2006 May;7(3):239-46. doi: 10.1007/s11934-006-0027-8. Curr Urol Rep. 2006. PMID: 16630528 Review.

4

Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.

Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. Rini BI, et al. Among authors: fong l. Cancer. 2006 Jul 1;107(1):67-74. doi: 10.1002/cncr.21956. Cancer. 2006. PMID: 16736512 Free article. Clinical Trial.

5

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.

Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. Small EJ, et al. Among authors: fong l. Clin Cancer Res. 2007 Mar 15;13(6):1810-5. doi: 10.1158/1078-0432.CCR-06-2318. Clin Cancer Res. 2007. PMID: 17363537 Clinical Trial.

6

Immunotherapy for prostate cancer.

Fong L, Small EJ. Fong L, et al. Curr Oncol Rep. 2007 May;9(3):226-33. doi: 10.1007/s11912-007-0026-z. Curr Oncol Rep. 2007. PMID: 17430695 Review.

7

SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade.

Fassò M, Waitz R, Hou Y, Rim T, Greenberg NM, Shastri N, Fong L, Allison JP. Fassò M, et al. Among authors: fong l. Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3509-14. doi: 10.1073/pnas.0712269105. Epub 2008 Feb 26. Proc Natl Acad Sci U S A. 2008. PMID: 18303116 Free PMC article.

8

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.

Kavanagh B, O'Brien S, Lee D, Hou Y, Weinberg V, Rini B, Allison JP, Small EJ, Fong L. Kavanagh B, et al. Among authors: fong l. Blood. 2008 Aug 15;112(4):1175-83. doi: 10.1182/blood-2007-11-125435. Epub 2008 Jun 3. Blood. 2008. PMID: 18523152 Free PMC article. Clinical Trial.

9

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.

Fong L, Small EJ. Fong L, et al. J Clin Oncol. 2008 Nov 10;26(32):5275-83. doi: 10.1200/JCO.2008.17.8954. Epub 2008 Oct 6. J Clin Oncol. 2008. PMID: 18838703 Review.

10

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ. Fong L, et al. Cancer Res. 2009 Jan 15;69(2):609-15. doi: 10.1158/0008-5472.CAN-08-3529. Cancer Res. 2009. PMID: 19147575 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

681 results

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

681 results